Effects of nanoparticles with hydrotropic nicotinamide on tacrolimus: Permeability through psoriatic skin and antipsoriatic and antiproliferative activities

International Journal of Nanomedicine

Volumn 12, Issue , 2017, Pages 1485-1497

  Wan, Tao ^a   Pan, Wenhui ^a   Long, Yueming ^a   Yu, Kaiyue ^a   Liu, Sibo ^a   Ruan, Wenyi ^a   Pan, Jingtong ^a   Qin, Mengyao ^a   Wu, Chuanbin ^a   Xu, Yuehong ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antiproliferation; Nanoparticles; Nicotinamide; Percutaneous delivery; Psoriasis; Tacrolimus

Indexed keywords

CLOBETASOL PROPIONATE; NANOPARTICLE; NICOTINAMIDE; TACROLIMUS; AMINOQUINOLINE DERIVATIVE; CHOLESTEROL; DERMATOLOGICAL AGENT; HYALURONIC ACID; IMIQUIMOD;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; ANTIPSORIATIC ACTIVITY; ARTICLE; CANCER CELL LINE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFECT; HACAT CELL LINE; HISTOPATHOLOGY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX; RAW 264.7 CELL LINE; SKIN PENETRATION; SKIN PERMEABILITY; ANIMAL; BAGG ALBINO MOUSE; CELL LINE; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; HUMAN; PATHOLOGY; PERMEABILITY; PRECLINICAL STUDY; PROCEDURES; SKIN; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; ANIMALS; CELL LINE; CHOLESTEROL; DERMATOLOGIC AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; HYALURONIC ACID; MICE, INBRED BALB C; NANOPARTICLES; NIACINAMIDE; PERMEABILITY; PSORIASIS; SKIN; TACROLIMUS;

EID: 85014344841     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S126210     Document Type: Article

References (46)

1. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113(12): 1664-1675.
2. Hamminga EA, van der Lely AJ, Neumann HA, Thio HB. Chronic inflammation in psoriasis and obesity: implications for therapy. Med Hypotheses. 2006;67(4): 768-773.
3. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5): 496-509.
4. Gustafson CJ, Watkins C, Hix E, Feldman SR. Combination therapy in psoriasis: an evidence-based review. Am J Clin Dermatol. 2013;14(1): 9-25.
5. Jiang W, Zhu FG, Bhagat L, et al. A Toll-like receptor 7, 8, and 9 antagonist inhibits Th1 and Th17 responses and inflammasome activation in a model of IL-23-induced psoriasis. J Invest Dermatol. 2013;133(7): 1777-1784.
6. Boakye CH, Patel K, Doddapaneni R, Bagde A, Marepally S, Singh M. Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment. J Control Release. Epub 2016 May 8.
7. Depieri LV, Borgheti-Cardoso LN, Campos PM, et al. RNAi mediated IL-6 in vitro knockdown in psoriasis skin model with topical siRNA delivery system based on liquid crystalline phase. Eur J Pharm Biopharm. 2016;105: 50-58.
8. Desmet E, Bracke S, Forier K, et al. An elastic liposomal formulation for RNAi-based topical treatment of skin disorders: proof-of-concept in the treatment of psoriasis. Int J Pharm. 2016;500(1-2): 268-274.
9. Sala M, Elaissari A, Fessi H. Advances in psoriasis physiopathology and treatments: up to date of mechanistic insights and perspectives of novel therapies based on innovative skin drug delivery systems (ISDDS). J Control Release. 2016;239: 182-202.
10. Schoepe S, Schäcke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6): 406-420.
11. Honbo T, Kobayashi M, Hane K, Hata T, Ueda Y. The oral dosage form of FK-506. Transplant Proc. 1987;19(5 suppl 6): 17-22.
12. Kino T, Hatanaka H, Hashimoto M, et al. FK-506, a novel immunosuppressant isolated from a Streptomyces. I. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiot. 1987;40(9): 1249-1255.
13. Lythgoe M, Abraham S. Tacrolimus: an effective treatment in refractory psoriatic arthritis following biologic failure. Clin Exp Rheumatol. 2016;34(1 suppl 95): 12-13.
14. Yoon KH. Successful usage of tacrolimus (FK506) in resistant/relapsed rheumatic diseases. APLAR. J Rheumatol. 2004;7: 44-48.
15. Thomson AW. FK-506 - how much potential? Immunol Today. 1989;10(1): 6-9.
16. Tocci MJ, Matkovich DA, Collier KA, et al. The immunosuppressant FK506 selectively inhibits expression of early T cell activation genes. J Immunol. 1989;143(2): 718-726.
17. Thomson AW, Bonham CA, Zeevi A. Mode of action of tacrolimus (FK506): molecular and cellular mechanisms. Ther Drug Monit. 1995;17(6): 584-591.
18. Woo DK, James WD. Topical tacrolimus: a review of its uses in dermatology. Dermatitis. 2005;16(1): 6-21.
19. Goebel AS, Neubert RH, Wohlrab J. Dermal targeting of tacrolimus using colloidal carrier systems. Int J Pharm. 2011;404(1-2): 159-168.
20. Bos JD, Witkamp L, Zonnevald IM, et al. Systemic tacrolimus (FK 506) is effective for the treatment of psoriasis in a double-blind, placebo-controlled study. Arch Dermatol. 1996;132(4): 419-423.
21. American Academy of Dermatology [webpage on the Internet]. Psoriasis: Recommendations for Topical Tacrolimus and Pimecrolimus. Available from: https://www.aad.org/practice-tools/quality-care/clinical-guidelines/psoriasis/topical-therapy/recommendations-for-topical-tacrolimus-and-pimecrolimus. Accessed January 5, 2017.
22. Zonneveld IM, Rubins A, Jablonska S, et al. Topical tacrolimus is not effective in chronic plaque psoriasis - a pilot study. Arch Dermatol. 1998;134(9): 1101-1102.
23. Remitz A, Reitamo S, Erkko P, Granlund H, Lauerma AI. Tacrolimus ointment improves psoriasis in a microplaque assay. Br J Dermatol. 1999;141(1): 103-107.
24. Freeman AK, Linowski GJ, Brady C, et al. Tacrolimus ointment for the treatment of psoriasis on the face and intertriginous areas. J Am Acad Dermatol. 2003;48(4): 564-568.
25. Lebwohl M, Freeman AK, Chapman MS, et al; Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. J Am Acad Dermatol. 2004;51(5): 723-730.
26. Kroft EB, Erceg A, Maimets K, Vissers W, van der Valk PG, van de Kerkhof PC. Tacrolimus ointment for the treatment of severe facial plaque psoriasis. J Eur Acad Dermatol Venereol. 2005;19(2): 249-251.
27. Martin Ezquerra G, Sanchez Regana M, Herrera Acosta E, Umbert Millet P. Topical tacrolimus for the treatment of psoriasis on the face, genitalia, intertriginous areas and corporal plaques. J Drugs Dermatol. 2006;5(4): 334-336.
28. Pan W, Qin M, Zhang G, et al. Combination of hydrotropic nicotinamide with nanoparticles for enhancing tacrolimus percutaneous delivery. Int J Nanomedicine. 2016;11: 4037-4050.
29. van der Fits L, Mourits S, Voerman JS, et al. Imiquimod-induced psoriasis-like skin inflammation in mice is mediated via the IL-23/IL-17 axis. J Immunol. 2009;182(9): 5836-5845.
30. Sun J, Dou W, Zhao Y, Hu J. A comparison of the effects of topical treatment of calcipotriol, camptothecin, clobetasol and tazarotene on an imiquimod-induced psoriasis-like mouse model. Immunopharmacol Immunotoxicol. 2014;36(1): 17-24.
31. Qin S, Wen J, Bai XC, et al. Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis. Mol Med Rep. 2014;9(6): 2097-2104.
32. Ueyama A, Yamamoto M, Tsujii K, et al. Mechanism of pathogenesis of imiquimod-induced skin inflammation in the mouse: a role for interferon-alpha in dendritic cell activation by imiquimod. J Dermatol. 2014;41(2): 135-143.
33. An J, Li Z, Dong Y, Ren J, Huo J. Amentoflavone protects against psoriasis-like skin lesion through suppression of NF-κB-mediated inflammation and keratinocyte proliferation. Mol Cell Biochem. 2016;413(1-2): 87-95.
34. Guichard A, Humbert P, Tissot M, Muret P, Courderot-Masuyer C, Viennet C. Effects of topical corticosteroids on cell proliferation, cell cycle progression and apoptosis: in vitro comparison on HaCaT. Int J Pharm. 2015;479(2): 422-429.
35. Chorachoo J, Saeloh D, Srichana T, et al. Rhodomytrone as a potential anti-proliferative and apoptosis inducing agent in HaCaT keratinocyte cells. Eur J Pharmacol. 2016;772: 144-151.
36. Zhao Y, Sun J, Dou W, Hu JH. Curcumin inhibits proliferation of interleukin-22-treated HaCaT cells. Int J Clin Exp Med. 2015;8(6): 9580-9584.
37. Alvarez-Román R, Naik A, Kalia YN, Guy RH, Fessi H. Skin penetration and distribution of polymeric nanoparticles. J Control Release. 2004;99(1): 53-62.
38. Campbell CS, Contreras-Rojas LR, Delgado-Charro MB, Guy RH. Objective assessment of nanoparticle disposition in mammalian skin after topical exposure. J Control Release. 2012;162(1): 201-207.
39. Jenning V, Gysler A, Schäfer-Korting M, Gohla SH. Vitamin A loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm. 2008;49(3): 211-218.
40. Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016;13(10): 1461-1473.
41. Soma Y, Kashima M, Imaizumi A, Takahama H, Kawakami T, Mizoguchi M. Moisturizing effects of topical nicotinamide on atopic dry skin. Int J Dermatol. 2005;44(3): 197-202.
42. Wohlrab J, Kreft D. Niacinamide - mechanisms of action and its topical use in dermatology. Skin Pharmacol Physiol. 2014;27(6): 311-315.
43. Ungerstedt JS, Blömback M, Söderström T. Nicotinamide is a potent inhibitor of proinflammatory cytokines. Clin Exp Immunol. 2003;131(1): 48-52.
44. Virág L, Szabó C. The therapeutic potential of poly (ADP-ribose) polymerase inhibitors. Pharmacol Rev. 2002;54(3): 375-429.
45. Cui Y, Xing C, Ran Y. Molecular dynamics simulations of hydrotropic solubilization and self-aggregation of nicotinamide. J Pharm Sci. 2010; 99(7): 3048-3059.
46. Palombo R, Savini I, Avigliano L, et al. Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model. Cell Death Dis. 2016;7(8): e2344.